Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era
Jeremy Tey, Bok Ai Choo, Cheng Nang Leong, En Yun Loy, Lea Choung Wong, Keith Lim, Jiade Jay Lu, Wee Yao Koh, Jeremy Tey, Bok Ai Choo, Cheng Nang Leong, En Yun Loy, Lea Choung Wong, Keith Lim, Jiade Jay Lu, Wee Yao Koh
Abstract
The purpose of this study was to report the outcomes of patients with symptomatic locally advanced/recurrent gastric cancer treated with radiotherapy (RT) using modern 3-dimensional conformal techniques.We retrospectively reviewed patients who had palliative RT for index symptoms of gastric bleeding, pain, and obstruction. Study endpoints included symptom response, median survival, and treatment toxicity.Of 115 patients with median age of 77 years, 78 (67.8%) patients had metastatic disease at the time of treatment. Index symptoms were gastric bleeding, pain, and obstruction in 89.6%, 9.2%, and 14.3% of patients, respectively. Dose fractionation regimen ranged from 8-Gy single fraction to 40 Gy in 16 fractions. One hundred eleven patients (93.3%) were computed tomography (CT) planned. Median follow-up was 85 days. Response rates for bleeding, pain, and obstruction were 80.6% (83/103), 45.5% (5/11), and 52.9% (9/17), respectively, and median duration of response was 99 days, 233 days, and 97 days, respectively. Median survival was 85 days. Actuarial 12-month survival was 15.3%. There was no difference in response rates between low (≤39 Gy) and high (>39 Gy) biologically effective dose (BED) regimens (α/β ratio = 10). Median survival was significantly longer in patients who responded to RT compared with patients who did not (113.5 vs 47 days, P < 0.001). Three patients (2.6%) had grade 3 Common Toxicity Criteria equivalent toxicity (nausea/vomiting/anorexia).External beam RT delivered using 3-dimensional conformal techniques is highly effective and well tolerated in the local palliation of gastric cancer, with palliation lasting the majority of patient's lives. Short (≤39 Gy BED) RT schedules are adequate for effective symptom palliation. A phase II study of palliative gastric RT is ongoing.
Conflict of interest statement
The authors have no funding and conflicts of interest to disclose.
Figures
References
- Hundahl SA, Philips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921–932.
- Mantell BS. Radiotherapy for dysphagia due to gastric carcinoma. Br J Surg. 1982;69:69.
- Myint AS. The role of radiotherapy in the palliative treatment of gastrointestinal cancer. Eur J Gastroenterol Hepatol. 2000;12:381–390.
- Tsukiyama I, Akine Y, Kajiura Y, et al. Radiation therapy for advanced gastric cancer. Int J Radiat Oncol Biol Phys. 1988;15:123–127.
- Nordman E. The value of megavolt therapy in gastric carcinoma. Bull Cancer. 1976;63:217–222.
- Henderson IWD, Lipowska B, Lougheed MN, et al. Clinical evaluation of combined radiation and chemotherapy in gastrointestinal malignancies. Am J Roentgenol Radium Ther Nucl Med. 1968;102:545.
- Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3:373–378.
- Falkson G, Van Eden EB, Sandison AG. A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bis-chloroethyl nitrosourea plus radiotherapy in stomach cancer. Med Pediatr Oncol. 1976;2:111.
- Salazar OM, Rubin P, Hendrickson FR, et al. Single-dose half-body irradiation for the palliation of multiple bone metastases from solid tumor: Final RTOG report. Cancer. 1986;58:29–36.
- Tey J, Back MF, Shakespeare TP, et al. The role of palliative radiation therapy in symptomatic locally advanced gastric cancer. Int J Radiat Oncol Biol Phys. 2007;67:385–388.
- Kim MM, Rana V, Janjan NA, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47:421–427.
- Asakura H, Hashimoto T, Harada H, et al. Palliative radiotherapy for bleeding from advanced gastric cancer. Is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol. 2011;137:125–130.
- Duchesne GM, Bolger JJ, Griffiths GO, et al. A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09. Int J Radiat Oncol Biol Phys. 2000;47:379–388.
Source: PubMed